Icon plc

Powered by. It provides specialized services that span the entire lifecycle of product development. Bolster business development with timely opportunities.

ICON acquires HumanFirst, a cloud-based technology company for life sciences supporting precision measurement in patient centred clinical research. ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Advancements in Artificial Intelligence for site selection Using human-enabled AI to enhance decision-making and minimise risk Read the whitepaper. A multifaceted risk factor: Addressing obesity's impact across the disease spectrum Read the whitepaper. Optimising biotech funding whitepaper series Read the whitepapers. EMA guideline on computerised systems and electronic data in clinical trials Key considerations on the impact of the new framework of globally applicable standards. Navigating the regulatory labyrinth of technology in decentralised clinical trials Keeping up to date and implementing the latest guidelines.

Icon plc

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. Lambe retired from the board of directors in Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. Download as PDF Printable version. See also: Icon disambiguation. Irish pharmaceutical company. Traded as. Contract research organization Pharmaceutical Medical device Life sciences Consulting. ICON plc.

October

.

CEO Dr. Our world class team aided in the development of 30 customer drug and device approvals in the year, including breakthrough COVID vaccines and therapies. Additionally, a number of discussions have continued with customers contemplating an expanded or new strategic relationship with ICON, as the increased scale, innovative solutions and best in class performance of new ICON address unmet industry needs. This represents a year on year increase of In addition to the financial measures prepared in accordance with generally accepted accounting principles GAAP , this press release contains certain non-GAAP financial measures, including adjusted revenue, adjusted EBITDA, adjusted net income attributable to the Group and adjusted diluted earnings per share attributable to the Group. To assist investors and analysts with year-over-year comparability for the merged business, we have included Combined Company information.

Icon plc

The new ICON will have a renewed focus on leveraging data, applying technology and accessing diverse patient populations to speed up drug development. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland , ICON will operate from locations in 47 countries and have approximately 38, employees as of July 1, This press release contains forward-looking statements.

Havoc os

Jerome Kohlberg Jr. Chief Commercial Officer. Book consultation. Tools Tools. Hidden categories: Articles with short description Short description matches Wikidata Articles containing potentially dated statements from June All articles containing potentially dated statements. Buy Report View Sample. Market Access Expertise in mission-critical pricing, market access, and reimbursement. Chief Executive Officer; Director. Headquarters Ireland. Optimising biotech funding whitepaper series Read the whitepapers. Key Financial Charts. Crosstree Capital. In September, the company entered into a partnership with the U.

ICON acquires HumanFirst, a cloud-based technology company for life sciences supporting precision measurement in patient centred clinical research. ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Advancements in Artificial Intelligence for site selection Using human-enabled AI to enhance decision-making and minimise risk Read the whitepaper.

Select Item. Services for pharmaceutical, biotech and medical device industries. Market Access Expertise in mission-critical pricing, market access, and reimbursement. Retrieved Market Screener. Contact the team or request a demo to find out how our data can drive your business forward. Retrieved 30 November Outsourcing Pharma. Key Financial Charts. Chief Information Officer. Book consultation. The Irish Times. United States Government. How can we help? Retrieved 8 December